Remission of severe cold agglutinin disease Rituximab therapy

Remission of cold hemagglutinin disease induced by rituximab therapy.

Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximab.

, 81 infliximab naive RA patients and 47 healthy subjects as controls. At the same time and apart from the purposes of that study, we also had done a pathergy test in those subjects who agreed to participate, with the aim of determining the effect of the pathergy phenomenon on the response of BS patients to the tuberculin test. Informed consent was obtained from all subjects. The study was appr...

Cold agglutinin disease.

Cold agglutinin disease is a rare and poorly understood disorder affecting 15% of patients with autoimmune hemolytic anemia. We reviewed the clinical and pathologic features, prognosis, and management in the literature and describe our institutional experience to improve strategies for accurate diagnosis and treatment. Retrospective analysis identified 89 patients from our institution with cold...

Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity

Severe cold agglutinin disease with hemodynamic compromise requires rapid stabilization of the autoimmune hemolytic anemia as a bridge to the immunosuppressive effect of rituximab. Herein, we describe eculizumab treatment of severe complement-mediated hemolysis in a patient whose hemodynamic status deteriorated in spite of supportive blood transfusions and therapeutic plasma exchange.

Severe cold hemagglutinin disease (CHD) successfully treated with rituximab.